Current development of pyrazole–azole hybrids with anticancer potential

Abstract

Chemotherapy is a critical treatment modality for cancer patients, but multidrug resistance remains one of the major challenges in cancer therapy, creating an urgent need for the development of novel potent chemical entities. Azoles, particularly pyrazole, could interact with different biological targets and exhibit diverse biological properties including anticancer activity. Many clinically used anticancer agents own an azole moiety, demonstrating that azoles are privileged and pivotal templates in the discovery of novel anticancer chemotherapeutics. The present article is an attempt to highlight the recent advances in pyrazole–azole hybrids with anticancer potential and discuss the structure–activity relationships, covering articles published from 2018 to present, to facilitate the rational design of more effective anticancer candidates.